Camzyos: A Game-Changer in HCM Treatment and a High-Conviction Buy for BMY

The real-world data from the COLLIGO-HCM and WAYFARER-HCM studies has cemented Camzyos (mavacamten) as a transformative therapy for obstructive hypertrophic cardiomyopathy (oHCM). These studies, spanning four continents and a racially diverse cohort of 278 patients, demonstrate that 59.9% of patients achieved at least one NYHA class improvement by week 24, with 94.4% maintaining NYHA class II or below by week 96 [1]. Such durability of response, coupled with 90.3% of patients achieving mean LVOT gradients of ≤30 mm Hg by week 36, underscores Camzyos’s ability to address both functional capacity and hemodynamic obstruction—key unmet needs in oHCM management [1].

Safety remains a critical concern for any novel therapy, but Camzyos has shown a favorable profile in long-term use. Mean left ventricular ejection fraction (LVEF) remained above 61% throughout the 96-week follow-up, with only 4% of patients experiencing temporary interruptions due to LVEF ≤50% and 1.1% permanently discontinuing the drug [1]. The incidence of new-onset atrial fibrillation (2.9%) aligns with prior trial data, reinforcing the consistency of its safety profile [1]. These findings, combined with the drug’s inclusion in both ESC and AHA/ACC guidelines, position Camzyos as a standard of care for symptomatic oHCM patients who remain uncontrolled on first-line therapies [2].

Bristol Myers Squibb (BMY) has leveraged these real-world outcomes to expand global access to Camzyos. Regulatory approvals in over 50 countries and regions, including the U.S. and EU, reflect the drug’s therapeutic value [2]. To address affordability challenges—particularly in the U.S., where the annual list price is $110,000—BMY has launched patient support programs, ensuring broader adoption [2]. The global WAYFARER-HCM program’s data, showing consistent efficacy across diverse populations, further strengthens Camzyos’s market position and justifies its role as a high-conviction growth driver in BMY’s rare disease portfolio [1].

For investors, Camzyos represents a rare combination of clinical differentiation and strategic execution. Its first-in-class status as a cardiac myosin inhibitor, coupled with real-world evidence validating long-term efficacy and safety, creates a durable competitive moat. As BMY continues to scale access and integrate Camzyos into global treatment algorithms, the drug is poised to deliver sustained revenue growth, reinforcing BMY’s leadership in rare disease innovation.

Source:
[1] Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 [https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Presents-Real-World-Outcomes-of-Camzyos-mavacamten-Across-Four-Continents-at-the-European-Society-of-Cardiology-ESC-Congress-2025/default.aspx]
[2] Camzyos: A High-Conviction Growth Play in Rare Disease Innovation [https://www.ainvest.com/news/camzyos-high-conviction-growth-play-rare-disease-innovation-2508/]